度普利尤单抗在6个月至11岁特应性皮炎儿童中的安全性和有效性长达3年:一项III期开放标签扩展研究结果。
完整摘要 · 中文译文
背景:度普利尤单抗此前在随机对照试验(RCT)和长期开放标签扩展(OLE)研究中已证明,在年龄≥6个月的过敏性皮炎(AD)患者中,其安全性和有效性可持续长达2年。 目的:我们报告一项正在进行的OLE研究(LIBERTY PED OLE)在中重度AD年幼儿科患者中长达3年的安全性和有效性。 方法:既往参加过度普利尤单抗RCT、年龄≥6个月至11岁的中重度AD患儿接受开放标签度普利尤单抗治疗,每4周一次(200 mg:5至<15 kg;300 mg:15至<30 kg)或每2周一次(200 mg:30至<60 kg;300 mg:≥60 kg)。允许合并使用外用药物。在母研究基线或OLE研究基线至152周时评估安全性、有效性和生活质量(QoL)。 结果:共纳入180例6个月至5岁患者和383例6至11岁患者;分别有56.1%和65.3%完成第152周。最常见的药物相关治疗中出现的不良事件(TEAE)包括结膜炎(6个月至5岁组2.8%;6至11岁组2.6%)、过敏性结膜炎(2.8%;2.6%)和鼻咽炎(1.7%;2.1%)。度普利尤单抗使疗效从母研究基线和OLE研究基线持续改善至第152周。第152周时,湿疹面积和严重程度指数评分改善≥75%/90%(EASI-75/EASI-90)在90.3%/60.2%的患者(6个月至5岁)和89.1%/61.1%的患者(6至11岁)中实现。在其他临床疗效(AD评分[SCORA D]-50和体表面积)以及生活质量(婴幼儿/儿童皮炎生活质量指数)指标。 结论:在这项OLE研究中,度普利尤单抗长达3年的长期治疗在婴幼儿和中重度特应性皮炎(AD)儿童中显示出可接受的安全性特征和持续疗效,支持其在儿科患者中的使用[图形摘要可在线获取]。 临床试验注册:ClinicalTrials.gov标识符:NCT02612454。 特应性皮炎(AD,或湿疹)是一种以反复发作的皮疹和瘙痒为特征的炎症性疾病。它在儿童中常见,可持续数年或终生。度普利尤单抗是AD的一种先进治疗方法。我们评估了度普利尤单抗在6个月至11岁AD儿童中长达3年治疗的获益和安全性。LIBERTY PED OLE是一项针对AD儿童的正在进行的研究。患者根据体重接受度普利尤单抗治疗,并可继续使用药膏。本分析包括两个年龄组:6个月至5岁(180名儿童)和6-11岁(383名儿童)。其中分别有101名和250名儿童完成了3年访视(第152周)。最常见的不良反应为红眼,报告为“过敏性结膜炎”或“未进一步说明的结膜炎”(在每个年龄组中各发生率高达3%),以及鼻咽炎(流鼻涕、咽喉痛;每个年龄组约2%)。这些不良反应与较短度数普利尤单抗研究报告的相似。3年后,6个月至5岁儿童中有90%、6-11岁儿童中有89%达到EASI-75(疾病至少改善75% 重度特应性皮炎(AD)的严重程度和范围)。截至第152周,与研究开始时严重的生活质量损害相比,大多数患者报告疾病对日常活动的影响大幅减轻。总之,在6个月至11岁的儿童中,长达3年的度普利尤单抗治疗使特应性皮炎获得持续改善,且安全性特征可接受。
完整摘要 · 英文原文
BACKGROUND: Dupilumab previously demonstrated safety and efficacy in randomized controlled trials (RCTs) and long-term open-label extension (OLE) studies for up to 2 years in patients with atopic dermatitis (AD) aged ≥ 6 months. OBJECTIVE: We report safety and efficacy up to 3 years from an ongoing OLE study (LIBERTY PED OLE) in young pediatric patients with moderate-to-severe AD. METHODS: Children aged ≥ 6 months to 11 years with moderate-to-severe AD from prior dupilumab RCTs received open-label dupilumab every 4 weeks (200 mg: 5 to < 15 kg; 300 mg: 15 to < 30 kg) or every 2 weeks (200 mg: 30 to < 60 kg; 300 mg: ≥ 60 kg). Concomitant topical medications were permitted. Safety, efficacy, and quality of life (QoL) were assessed at parent study baseline or OLE study baseline through 152 weeks. RESULTS: One hundred and eighty patients 6 months to 5 years old and 383 patients 6 to 11 years old were enrolled; 56.1% and 65.3% completed week 152, respectively. The most frequent drug-related treatment-emergent adverse events (TEAEs) included conjunctivitis (2.8% in the 6 months to 5 years group; 2.6% in the 6 to 11 years group), allergic conjunctivitis (2.8%; 2.6%), and nasopharyngitis (1.7%; 2.1%). Dupilumab resulted in persistent efficacy improvements from parent study baseline and OLE study baseline to week 152. ≥ 75%/90% improvement in Eczema Area and Severity Index scores (EASI-75/EASI-90) at week 152 was achieved in 90.3%/60.2% of patients (6 months to 5 years) and 89.1%/61.1% (6 to 11 years). Similar outcomes were observed in other clinical efficacy (SCORing AD score [SCORAD]-50 and body surface area) and QoL (Infants'/Children's Dermatitis QoL Index) metrics. CONCLUSIONS: In this OLE study, long-term treatment with dupilumab for up to 3 years showed an acceptable safety profile and continued efficacy in infants and children with moderate-to-severe AD, supporting its use in pediatric patients [Graphical Abstracct available online]. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02612454. Atopic dermatitis (AD, or eczema) is an inflammatory disease with repeating episodes of skin rash and itch. It is common in children and can last for years or throughout life. Dupilumab is an advanced treatment for AD. We evaluated the benefits and safety of dupilumab treatment for up to 3 years in children aged 6 months to 11 years with AD. LIBERTY PED OLE is an ongoing study for children with AD. Patients receive dupilumab based on body weight and can continue using medicated skin creams. This analysis includes two age groups: 6 months to 5 years (180 children) and 6–11 years (383 children). Among these, 101 and 250 children, respectively, completed the 3-year visit (week 152). The most common side effects were red eye, reported as either “allergic conjunctivitis” or “conjunctivitis not further specified” (each occurring in up to 3% in each age group), and nasopharyngitis (runny nose, sore throat; around 2% in each age group). These side effects are similar to those reported in shorter dupilumab studies. After 3 years, 90% of children 6 months to 5 years old and 89% of children 6–11 years old achieved EASI-75 (at least 75% reduction in disease severity and extent of AD). By week 152, most patients reported substantially less disease impact on daily activities, compared with severe quality-of-life impairment at study start. In conclusion, in children aged 6 months to 11 years, up to 3 years of dupilumab treatment led to sustained improvement of AD with an acceptable safety profile.